Clinical Trials Browser

Interventional × Albumin-Bound Paclitaxel × Clear all

NCT04940286 2026-04-16

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05497778 2026-04-16

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07060807 2026-04-16

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Phase 3 Recruiting

Breast Neoplasms

NCT04481204 2026-04-15

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Phase 2 Active not recruiting

Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

NCT06096844 2026-04-15

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Phase 3 Recruiting

Lung Neoplasms

NCT07530445 2026-04-15

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

Phase 2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT03907475 2026-04-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Phase 2 Recruiting

Neoplasm Metastasis

NCT04310007 2026-04-13

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Lung Neoplasms

NCT04528680 2026-04-13

SC9/ABX

Phase 1/2 Active not recruiting

Glioblastoma, Gliosarcoma

NCT05422794 2026-04-13

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Phase 1 Recruiting

Triple Negative Breast Neoplasms

NCT05685602 2026-04-13

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Phase 1 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06743126 2026-04-13

SUPRAME

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

NCT06841354 2026-04-13

TroFuse-011

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT07423078 2026-04-13

WOLF

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT05624918 2026-04-08

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Phase 2 Recruiting

Gastrointestinal

Pancreatic Adenocarcinoma

NCT05632328 2026-04-08

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05753306 2026-04-08

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

Phase 2 Recruiting

GastrointestinalOther neoplasm

Gastric Adenocarcinoma

NCT06958328 2026-04-08

LAP100

Phase 3 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05382299 2026-04-06

ASCENT-03

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT02077881 2026-04-03

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Phase 1/2 Completed

157 enrolled 18 charts

Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Phase 2 Active not recruiting

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT04251533 2026-04-03

EPIK-B3

Phase 3 Terminated

137 enrolled 21 charts

Triple Negative Breast Neoplasms

NCT05624996 2026-04-03

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT06132958 2026-04-03

TroFuse-005

Phase 3 Active not recruiting

Endometrial Neoplasms

NCT02945800 2026-04-02

Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Phase 2 Completed

59 enrolled 11 charts

Recurrence, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma

NCT03606967 2026-04-02

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Phase 2 Recruiting

Salivary Gland Neoplasms

NCT06312176 2026-04-02

MK-2870-010

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT06745882 2026-04-02

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06483555 2026-04-01

PANGEA

Phase 1/2 Recruiting

DermatologicGastrointestinal

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT04104672 2026-03-31

ARC-8

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07076121 2026-03-31

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Phase 2/3 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT01525966 2026-03-30

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

Phase 2 Active not recruiting

67 enrolled 12 charts

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05586516 2026-03-30

A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer

Phase 1/2 Completed

Gastrointestinal

Fibrosis, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT06904378 2026-03-30

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1/2 Recruiting

Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

NCT05017012 2026-03-27

MK-3475A-C18

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT06953323 2026-03-27

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT06998940 2026-03-27

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Phase 3 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05771480 2026-03-25

TOURMALINE

Phase 3 Active not recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT04233866 2026-03-23

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04266249 2026-03-23

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Phase 2 Active not recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT06493019 2026-03-23

Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

Phase 2 Recruiting

Gastrointestinal

Anus Neoplasms

NCT04894643 2026-03-20

PARC

Phase NA Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07394387 2026-03-19

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT07483554 2026-03-19

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

Phase 2 Not yet recruiting

Gastrointestinal

CLDN18.2 Positive

NCT04165070 2026-03-16

MK-3475-01A

Phase 1/2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03164616 2026-03-13

POSEIDON

Phase 3 Active not recruiting

1,186 enrolled 26 charts 2 FDA

Non Small Cell Lung Cancer NSCLC

NCT05285358 2026-03-13

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

Phase 1 Recruiting

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT06704724 2026-03-13

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Phase 1 Active not recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT04895358 2026-03-11

KEYNOTE-B49

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis